Are weight loss patches safe
Whether this mechanism translates into greater weight loss than dual-agonist therapies remains a hypothesis no head-to-head clinical trials have yet been conducted
GLP-1 Receptor Agonist Discontinuation Among Patients with Obesity and/or Type 2 Diabetes
[1] [3] Given that obesity is itself a major cardiovascular risk factor, significant weight loss is generally associated with improvements in blood pressure, lipid profiles, and markers of systemic inflammation, all of which may benefit heart health
Both younger adults seeking to prevent weight-related health complications and older adults managing existing conditions showed meaningful responses in clinical trials
Additionally, cardiovascular and metabolic benefits observed at therapeutic doses might be partially retained at lower doses, though this remains speculative without dedicated dose-finding studies